{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122784","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.584213+00:00","generated_at":"2026-05-30T03:59:36.701431+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Upstream Bio Q3 net loss $16.0M; IPO raises $293M, extends cash runway through 2027","bullets":["Net loss of $16.0M in Q3 2024 vs $3.1M loss in Q3 2023, driven by higher R&D and G&A costs.","Cash, equivalents and short-term investments $220.7M at Sept 30, 2024; with IPO proceeds, runway through 2027.","Phase 2 trial of verekitug in severe asthma data expected H2 2026; CRSwNP data H2 2025; COPD trial starts H2 2025.","Upsized IPO raised ~$293M gross (17.25M shares at $17.00); Daniella Beckman appointed to board as independent director.","Phase 1b data showed verekitug 50% greater FeNO reduction vs tezepelumab; supports Q12W and Q24W dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122784","json":"https://secwatch.observer/filing/0000950170-24-122784.json","markdown":"https://secwatch.observer/filing/0000950170-24-122784.md","text":"https://secwatch.observer/filing/0000950170-24-122784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024122784/0000950170-24-122784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024122784/upb-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:59:36.701431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}